The global market for Subcutaneous Implantable Defibrillator Systems is projected to experience robust growth over the next ...
The US FDA study is intended to evaluate the system for treating life-threatening ventricular tachyarrhythmias.
AtaCor Medical announced today that it entered a financing worth up to $75 million to support its U.S. FDA pivotal study.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback